PRN: 'World Revenues for Epigenetic Therapies and Technologies Will Reach $2.73bn in 2015' Says visiongain

20/ott/2011 15.01.16 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

'World Revenues for Epigenetic Therapies and Technologies Will Reach $2.73bn in 2015' Says visiongain


LONDON, October 20, 2011 /PRNewswire/ --

A new report by visiongain, a London-based business information company, predicts that world revenues for epigenetic therapies and technologies will reach $2.73bn in 2015. Strong uptake of epigenetic technologies, including drug discovery and research tools, will drive this growth. This overall market will grow with a CAGR of 16% between 2010 and 2015, according to Epigenetic Therapies and Technologies: World Market Prospects 2011-2021, published in October 2011.

Therapies will remain the largest source of revenue in the epigenetics market. Four products are available; world revenues from these totalled $0.76bn in 2010. Increased uptake of those drugs, as well as the launch of new therapies, will drive growth in this market sector to 2021, visiongain's study found. As of September 2011, there were five histone deacetylase (HDAC) inhibitors in phase II clinical studies and beyond. The launch of cancer diagnostics based on epigenetic biomarkers will also drive overall market growth from 2011 to 2021.

Richard Lang, pharmaceutical industry analyst, said: "Epigenetics is an exciting and fast-growing area of research. In a little over a decade, the field has moved from early research to the development of second-generation therapies. Greater understanding of the biology behind epigenetics in disease will help improve the selectivity of targeted epigenetic therapies over the next 10 years."  

In 2010, revenues from the US, Western Europe and Japan dominated the world epigenetic therapies and technologies market, visiongain's study found. The US accounted for around two thirds of therapy revenues in that year. That dominance will continue as new therapies and diagnostic technologies are launched in those markets first. By 2015, the US will account for over half of the world epigenetics market. Many research institutions are in the US and Western Europe; along with emerging biotechnology companies, they will provide the greatest demand for epigenetic research technologies.

Visiongain forecasts that the overall epigenetic therapies and technologies market will grow strongly to 2021. Increased governmental support and further investment from industry will help move early research into clinical testing and beyond. Further efforts in epigenetic research will identify more epigenetic biomarkers in diseases, broadening the scope for epigenetic therapies and other products. This new study adds to visiongain's wide range of analytical reports for healthcare and other industries.

To view sample pages please click on:

To request an exec summary please email Sara Peerun
Tel +44(0)207-336-6100

Executive Summary
1.1 Epigenetic Therapies and Technologies: World Market Review
1.2 Chapter Breakdown
1.3 Research and Analysis Methods

2. Introduction to Epigenetics in Medicine
2.1 Definition of Epigenetics
2.1.1 Epigenetic Mechanisms
2.2 Epigenetics and Disease
2.2.1 Epigenetics and Cancer
2.2.2 Epigenetics and Other Diseases
2.3 Epigenetic Therapies
2.4 Epigenetics in Drug Discovery and Development
2.4.1 Bisulphite Screening
2.4.2 Chromatin Immunoprecipitation (ChIP)
2.5 Epigenetics and Diagnosis

3. The Epigenetic Therapies and Technologies Market 2011-2021
3.1 The Epigenetic Therapies and Technologies Market 2010
3.2 The Epigenetic Therapies and Technologies Market: Overall Revenue Forecast 2011-2021
3.3 Epigenetic Therapies Submarket 2010
3.3.1 Epigenetic Therapies Submarket: Revenue Forecast 2011-2021
3.3.2 DNMT Inhibitors Myelodysplastic Syndromes (MDS)
3.3.3 Vidaza Vidaza: Revenue Forecast 2011-2021
3.3.4 Dacogen Dacogen: Revenue Forecast 2011-2021
3.3.5 HDAC Inhibitors Cutaneous T Cell Lymphoma (CTCL)
3.3.6 Zolinza Zolinza: Revenue Forecast 2011-2021
3.3.7 Istodax Peripheral T Cell Lymphoma (PTCL) Istodax: Revenue Forecast 2011-2021
3.4 Epigenetic Diagnostics Submarket 2010
3.4.1 Epigenetic Diagnostics Submarket: Revenue Forecast 2011-2021 Colorectal Cancer Breast Cancer Prostate Cancer Other Cancers
3.5 Epigenetic Technologies Submarket 2010
3.5.1 Epigenetic Technologies Submarket: Revenue Forecast 2011-2021 DNA Methylation Analysis Histone Modification Analysis Next-Generation Sequencing Technologies

4. Leading National Epigenetic Markets 2011-2021
4.1 Leading National Markets: Revenue Forecasts 2011-2021
4.2 The US: Revenues 2011-2021
4.3 The European Market: Revenues 2011-2021
4.4 Japan: Revenues 2011-2021
4.5 Epigenetics in Emerging Markets

5. Epigenetic Therapy R&D Pipeline in 2011
5.1 HDAC Inhibitors
5.1.1 PXD-101 (Belinostat Topotarget/Spectrum Pharmaceuticals)
5.1.2 LBH589 (Panobinostat, Novartis)
5.1.3 Entinostat (Syndax Pharmaceuticals)
5.1.4 4SC-201 (Resminostat, 4SC)
5.1.5 MGCD-0103 (Mocetinostat, MethylGene)
5.1.6 SB939 (S*BIO)
5.1.7 ACY-1215 (Acetylon Pharmaceuticals)
5.1.8 EVP-0334 (EnVivo Pharmaceuticals/MethylGene)
5.1.9 CHR-2845 (Tefinostat, Chroma Therapeutics)
5.1.10 CXD101 (Celleron Therapeutics)
5.1.11 RG2833 (Repligen)
5.1.12 PCI-24781 (Pharmacyclics/Les Laboratoires Servier)
5.1.13 JNJ26481585 (Centocor Research & Development)
5.1.14 Valproic Acid
5.2 DNMT Inhibitors
5.2.1 SGI-110 (Astex Pharmaceuticals)
5.2.2 CP-4200 (Clavis Pharma)
5.3 Histone Methyltransferase Inhibitors
5.3.1 DOT1L Inhibitors
5.3.2 EZH2 Inhibitors
5.4 Other Epigenetic Pathways

6. Leading Companies in the Epigenetics Market in 2011
6.1 Epigenetic Therapy Companies
6.1.1 Celgene
6.1.2 Eisai
6.1.3 Merck & Co.
6.1.4 Clinical-Stage Companies 4SC Astex Pharmaceuticals Chroma Therapeutics MethylGene Spectrum Pharmaceuticals Syndax Pharmaceuticals
6.1.5 Pre-Clinical Stage Companies CellCentric Constellation Pharmaceuticals EpiTherapeutics Epizyme IkerChem
6.2 Epigenetic Diagnostics Companies
6.2.1 Epigenomics
6.2.2 Exact Sciences
6.2.3 MDxHealth
6.2.4 Orion Genomics
6.2.5 PrognosDx Health
6.3 Epigenetic Technology Companies
6.3.1 Active Motif
6.3.2 Cellzome
6.3.3 Diagenode
6.3.4 EMD Millipore
6.3.5 Epigentek
6.3.6 Life Technologies
6.3.7 Roche

7. Epigenetic Therapies and Technologies: Industry Trends 2011-2021
7.1 Strengths and Weaknesses in the Epigenetic Therapies and Technologies Market in 2010
7.2 Opportunities and Threats in the Epigenetic Therapies and Technologies Market 2011-2021
7.2.1 Big Pharma Entering the Industry GSK
7.2.2 Business Models for Epigenetics
7.2.3 A Rapidly Expanding Pipeline
7.2.4 An Explanation for - and a Solution to - Drug Resistance?
7.2.5 Epigenetics and Stem Cells Induced Pluripotent Stem Cells (iPSCs)
7.2.6 A Burgeoning Field of Research Costs of Research
7.2.7 Non-Commercial Support for Research Global Collaboration Funding Epigenetic Research in the EU
7.2.8 The Ethics of Epigenetics
7.3 The Impact of the Environment
7.3.1 An Ageing Global Population
7.4 Therapeutic Potential Beyond Cancer
7.4.1 Autoimmune Diseases Rheumatoid Arthritis Lupus
7.4.2 Neurodegenerative Diseases Alzheimer's Disease
7.4.3 Psychiatric Disorders
7.4.4 Diabetes and Obesity

8. Research Interviews
8.1 Dr Anthony Brown, Scientific Director, CellCentric
8.1.1 Collaboration in Epigenetic Research and Drug Development Collaboration in the EU
8.1.2 Potential for New Classes of Epigenetic Enzyme
8.1.3 Specificity in HDAC Inhibitors
8.1.4 Epigenetics as Combination Therapies
8.1.5 The Context of Epigenetic Modifications
8.1.6 Challenges in Epigenetic Drug Development
8.2 Dr Martin Bonde, CEO, EpiTherapeutics
8.2.1 Potential for Histone Methyltransferase Inhibitors
8.2.2 Future of Epigenetics Research
8.2.3 Challenges in Developing Epigenetic Therapies
8.2.4 Benefits of University Spin-Outs

9. Conclusions from Our Study
9.1 Growth in the Epigenetic Therapies and Technologies Market 2011-2021
9.1.1 Diagnostics Set for Rapid Growth
9.1.2 Continued Dominance of Developed Markets
9.2 Global Collaboration
9.3 Applications in Cancer Will Remain Important in this Field

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Telecoms, Energy, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to or call her on +44(0)207-336-6100

blog comments powered by Disqus è un servizio offerto da Factotum Srl